Molecular Biology of Pituitary Adenomas.

Pituitary adenomas are benign tumors, but still cause significant morbidity and in some cases increases in mortality. Surgical resection is not without risks, and approximately 40% of adenomas are incompletely resected. Medical therapies such as dopamine agonists, somatostatin analogues, and growth hormone antagonists are associated with numerous side effects. Understanding the molecular biology of pituitary adenomas may yield new therapeutic approaches. Additional studies are needed to help determine which genes or pathways are "drivers" of tumorigenesis and should be therapeutic targets. Further studies may also enable pituitary adenoma stratification to tailor treatment approaches.

• Publication year

  2019

• Venue

  Neurosurgery clinics of North America

• Publication date

  2019-07-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NEC.2019.05.001PMID 31471046
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correction to: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas

  2022cited by this paper
• Thyrotropinomas

  2021cited by this paper
• The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes

  2018cited by this paper
• CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

  2018cited by this paper
• Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas

  2018cited by this paper
• Let-7c inhibits migration and epithelial–mesenchymal transition in head and neck squamous cell carcinoma by targeting IGF1R and HMGA2

  2018cited by this paper
• Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management

  2018cited by this paper
• Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas

  2018cited by this paper
• The 2017 WHO classification of pituitary adenoma: overview and comments

  2018cited by this paper
• Identification of recurrent USP48 and BRAF mutations in Cushing’s disease

  2018cited by this paper
• Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

  2017cited by this paper
• Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas

  2017cited by this paper
• Overview of the 2017 WHO Classification of Pituitary Tumors

  2017cited by this paper
• Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke’s cell morphology

  2017cited by this paper
• Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

  2017cited by this paper
• Aurora kinases: novel therapy targets in cancers

  2017cited by this paper
• Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas

  2017cited by this paper
• Gene expression profiling of fast- and slow-growing non-functioning gonadotroph pituitary adenomas.

  2017cited by this paper
• Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease

  2017cited by this paper
• Functional Gonadotroph Adenomas: Case Series and Report of Literature.

  2016cited by this paper
• Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management

  2016cited by this paper
• MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN

  2016cited by this paper
• Pituitary Medicine From Discovery to Patient-Focused Outcomes.

  2016cited by this paper
• Novel Genetic Causes of Pituitary Adenomas

  2016cited by this paper
• The genome-wide mutational landscape of pituitary adenomas

  2016cited by this paper
• MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1

  2015cited by this paper
• A Patient With a Thyrotropin-Secreting Microadenoma and Resistance to Thyroid Hormone (P453T).

  2015cited by this paper
• TSH-secreting pituitary adenoma: benefits of pre-operative octreotide

  2015cited by this paper
• Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development

  2015cited by this paper
• Recurrent gain-of-function USP8 mutations in Cushing's disease

  2015cited by this paper
• USP8 mutation in Cushing's disease

  2015cited by this paper
• Growth hormone tumor histological subtypes predict response to surgical and medical therapy

  2015cited by this paper
• Carney complex: an update.

  2015cited by this paper
• A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease

  2015cited by this paper
• Progress in the Diagnosis and Classification of Pituitary Adenomas

  2015cited by this paper
• AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling

  2014cited by this paper
• Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

  2014cited by this paper
• Mutations in the deubiquitinase gene USP8 cause Cushing's disease

  2014cited by this paper
• MEN1-tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2

  2014cited by this paper
• Growth hormone is a cellular senescence target in pituitary and nonpituitary cells

  2013cited by this paper
• Whole-exome sequencing studies of nonfunctioning pituitary adenomas.

  2013cited by this paper
• Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease

  2013cited by this paper
• A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.

  2013cited by this paper
• Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Cure of a thyrotrophin (TSH)‐secreting pituitary adenoma by medical therapy

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Dopamine agonist-resistant prolactinomas.

  2011cited by this paper
• Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors

  2011cited by this paper
• MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas

  2011cited by this paper
• Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.

  2010cited by this paper
• The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice via activation of Wnt and ERK1/2 MAPK pathways

  2010cited by this paper
• Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK)

  2010cited by this paper
• HMGA2: A pituitary tumour subtype-specific oncogene?

  2010cited by this paper
• Acromegaly pathogenesis and treatment.

  2009cited by this paper
• Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.

  2008cited by this paper
• Pituitary Tumors and Hyperplasia in Multiple Endocrine Neoplasia Type 1 Syndrome (MEN1): A Case-Control Study in a Series of 77 Patients Versus 2509 Non-MEN1 Patients

  2008cited by this paper
• p21Cip1 restrains pituitary tumor growth

  2008cited by this paper
• Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission

  2007cited by this paper
• Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.

  2007cited by this paper
• Activation of p53 by MEG3 Non-coding RNA*

  2007cited by this paper
• A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.

  2007cited by this paper
• HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

  2006cited by this paper
• E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression

  2006cited by this paper
• Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes.

  2005cited by this paper
• Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.

  2005cited by this paper
• An Unliganded Thyroid Hormone β Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells

  2004cited by this paper
• Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation

  2004cited by this paper
• Crooke's Cell Adenoma of the Pituitary: An Aggressive Variant of Corticotroph Adenoma

  2003cited by this paper
• PDGF-D is a potent transforming and angiogenic growth factor

  2003cited by this paper
• The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.

  2003cited by this paper
• The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.

  2002cited by this paper
• Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas

  2001cited by this paper
• The surgical management of pituitary adenomas in a series of 3,093 patients.

  2001cited by this paper
• Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance.

  2001cited by this paper
• Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex

  2000cited by this paper
• Hypermethylation of the p16/CDKN2A/MTS1 gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas

  1999cited by this paper
• Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor.

  1997cited by this paper
• Thyrotropin-secreting pituitary adenomas.

  1996cited by this paper
• Clonal origin of pituitary adenomas.

  1990cited by this paper
• Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas

  1987cited by this paper

• The PitNET Puzzle: From Zero to Linking Molecular Behavior with Neurosurgical Aspects

  2025cites this paper
• Liquid Biopsy in Pituitary Neuroendocrine Tumors—Potential Biomarkers for Diagnosis, Prognosis, and Therapy

  2025cites this paper
• A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions

  2025cites this paper
• Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma

  2025cites this paper
• Exploring the Role of the TAS2R16 Protein and Its Single Nucleotide Variants in Pituitary Adenoma Development

  2024cites this paper
• The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review

  2023cites this paper
• CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma

  2023cites this paper
• Benign and Malignant Tumors of the Pituitary Gland.

  2023cites this paper
• Recent advancements in the molecular biology of pituitary adenomas

  2022cites this paper
• Pituitary adenomas.

  2022cites this paper
• Pituitary tumour types in dogs and cats.

  2021cites this paper
• [68Ga]-DOTATATE PET in the Central Nervous System

  2021cites this paper
• Optimizing Consistency and the Scope of Excellence in Pituitary Surgery.

  2021cites this paper
• Management of prolactinomas in children and adolescents; which factors define the response to treatment?

  2021cites this paper
• GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer

  2021cites this paper
• MicroRNA-29-3p regulates the β-catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells

  2021cites this paper
• Sellar Tumors.

  2020cites this paper
• The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis

  2019cites this paper